Filing Flows › Companies › PTC Therapeutics › Timeline
PTC Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−9.9% to $65.44
PTC Therapeutics (PTCT) stock fell 10% over the last 252 sessions, to $65.44. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 19 Form 144 notices of planned sales, and the company filed 6 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 29, 2026 | Earnings | Earnings: missed the EPS estimate by -243.9% | +2.3% (+2.6% vs SPY) | +9.0% (+9.7% vs SPY) | — |
| Oct 7, 2026 | Form 144 | Form 144: Section Six Partners, L.P. plans to sell $644K | −0.7% (−0.5% vs SPY) | −6.1% (−6.0% vs SPY) | +7.9% (+9.5% vs SPY) |
| Oct 6, 2026 | Form 144 | Form 144: Mark Boulding plans to sell $28K | +0.1% (−0.5% vs SPY) | −1.2% (−1.6% vs SPY) | +6.8% (+9.5% vs SPY) |
| Oct 5, 2026 | Form 144 | Form 144: Mark Boulding plans to sell $105K | +0.3% (−0.4% vs SPY) | +1.9% (+0.8% vs SPY) | −4.2% (−1.8% vs SPY) |
| Sep 30, 2026 | Form 144 | Form 144: Steele Glenn Jr. Md Phd plans to sell $782K | −0.3% (−0.1% vs SPY) | −2.0% (−3.9% vs SPY) | −3.0% (−4.1% vs SPY) |
| Sep 9, 2026 | Form 144 | Form 144: Section Six Partners, L.P. plans to sell $2.7M | −1.8% (−1.3% vs SPY) | −4.7% (−3.6% vs SPY) | −8.5% (−10.2% vs SPY) |
| Aug 28, 2026 | 8-K | Material definitive agreement | −0.8% (−0.5% vs SPY) | −1.1% (−1.2% vs SPY) | −7.6% (−7.2% vs SPY) |
| Aug 19, 2026 | Form 144 | Form 144: Michael Schmertzler plans to sell $3.6M | +1.4% (+1.2% vs SPY) | +1.2% (+1.3% vs SPY) | −6.6% (−6.0% vs SPY) |
| Aug 19, 2026 | Form 144 | Form 144: Section Six Partners, L.P. plans to sell $3.6M | +1.4% (+1.2% vs SPY) | +1.2% (+1.3% vs SPY) | −6.6% (−6.0% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Mark Boulding plans to sell $202K | +1.6% (+2.1% vs SPY) | −2.7% (−1.3% vs SPY) | −8.8% (−6.3% vs SPY) |
| Aug 4, 2026 | Form 144 | Form 144: Matthew Klein plans to sell $706K | +1.4% (−0.4% vs SPY) | +9.1% (+7.1% vs SPY) | +3.5% (+3.0% vs SPY) |
| Jul 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | −10.5% (−11.2% vs SPY) | −6.4% (−9.9% vs SPY) | −7.5% (−11.1% vs SPY) |
| Jul 30, 2026 | Earnings | Earnings: beat the EPS estimate by 170.6% | +1.4% (−0.3% vs SPY) | −7.3% (−12.7% vs SPY) | −3.7% (−9.2% vs SPY) |
| Jul 14, 2026 | Form 144 | Form 144: Pierre Gravier plans to sell $281K | −4.1% (−4.4% vs SPY) | −4.2% (−3.2% vs SPY) | −9.9% (−12.7% vs SPY) |
| Jul 9, 2026 | Form 144 | Form 144: Mary L. Smith plans to sell $1.4M | +1.1% (+0.3% vs SPY) | −11.6% (−12.9% vs SPY) | −22.3% (−25.4% vs SPY) |
| Jul 9, 2026 | Form 144 | Form 144: Neil Gregory Almstead plans to sell $222K | +1.1% (+0.3% vs SPY) | −11.6% (−12.9% vs SPY) | −22.3% (−25.4% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: Neil Gregory Almstead plans to sell $2.2M | +4.3% (+4.8% vs SPY) | −4.9% (−4.6% vs SPY) | −21.2% (−23.9% vs SPY) |
| Jul 6, 2026 | Form 144 | Form 144: Mark Boulding plans to sell $427K | +2.5% (+1.6% vs SPY) | +1.8% (+0.5% vs SPY) | −20.2% (−21.9% vs SPY) |
| Jul 6, 2026 | Form 144 | Form 144: Neil Gregory Almstead plans to sell $1.9M | +2.5% (+1.6% vs SPY) | +1.8% (+0.5% vs SPY) | −20.2% (−21.9% vs SPY) |
| Jun 26, 2026 | Form 144 | Form 144: Neil Gregory Almstead plans to sell $693K | −0.1% (+0.6% vs SPY) | −1.4% (−2.8% vs SPY) | −10.9% (−11.5% vs SPY) |
| Jun 25, 2026 | Form 144 | Form 144: Neil Gregory Almstead plans to sell $1.8M | +0.1% (0.0% vs SPY) | −3.7% (−5.4% vs SPY) | −9.4% (−10.2% vs SPY) |
| Jun 24, 2026 | Form 144 | Form 144: Neil Gregory Almstead plans to sell $453K | +2.7% (+2.8% vs SPY) | −0.7% (−2.4% vs SPY) | −4.6% (−5.2% vs SPY) |
| Jun 22, 2026 | Form 144 | Form 144: Neil Gregory Almstead plans to sell $1.9M | +2.5% (+2.8% vs SPY) | +6.7% (+9.1% vs SPY) | −0.6% (−0.8% vs SPY) |
| Jun 18, 2026 | 8-K | Material definitive agreement | +2.5% (+2.8% vs SPY) | +6.7% (+9.1% vs SPY) | −0.6% (−0.8% vs SPY) |
| Jun 9, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.4% (+1.1% vs SPY) | −0.6% (−2.4% vs SPY) | +14.1% (+11.5% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 93.2% | −3.2% (−2.9% vs SPY) | +9.9% (+8.7% vs SPY) | +6.4% (+5.9% vs SPY) |
| Mar 25, 2026 | 8-K | Directors and officers: departures, appointments, pay | +3.4% (+2.8% vs SPY) | +5.4% (+5.8% vs SPY) | +6.1% (−2.1% vs SPY) |
| Feb 19, 2026 | Earnings | Earnings: missed the EPS estimate by -343.5% | +1.4% (+1.7% vs SPY) | −1.7% (−2.7% vs SPY) | −2.7% (+1.2% vs SPY) |
| Dec 29, 2025 | 8-K | Material definitive agreement | −1.9% (−1.8% vs SPY) | −1.2% (−1.8% vs SPY) | −1.6% (−2.5% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → PTC Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.